 Connection
Frank Scott to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Frank Scott has written about Antibodies, Monoclonal, Humanized.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.028 |
|
|
|
-
Scott FI, Luo M, Shah Y, Lasch K, Vajravelu RK, Mamtani R, Fennimore B, Gerich ME, Lewis JD. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. J Crohns Colitis. 2020 Jun 19; 14(5):575-587.
Score: 0.468
-
Scott FI, Shah Y, Lasch K, Luo M, Lewis JD. Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model. Inflamm Bowel Dis. 2018 01 18; 24(2):286-295.
Score: 0.396
-
Ahmed W, Scott FI. Closing the Gap: the Real-World Risk of Serious Infections With Vedolizumab in Comparison With Anti-TNF Therapy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022 02; 20(2):e28-e30.
Score: 0.125
-
Ananthakrishnan AN, Murad MH, Scott FI, Agrawal M, Haydek JP, Limketkai BN, Loftus EV, Singh S. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis. Gastroenterology. 2024 Dec; 167(7):1460-1482.
Score: 0.040
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|